Author + information
- Munis Raza,
- Michelle Colpitts,
- Lenora Eberhart and
- David Langholz
Background: Cardiovascular disease is the second leading cause of death among cancer survivors. Chemotherapy is associated with increased risk of non-ischemic cardiomyopathy and heart failure. The incidence of cardiomyopathy is dependent upon the class of chemotherapeutics; there is also a reported effect from treatment duration, gender and age. Early initiation of cardioprotective therapy, such as Carvedilol, based on echocardiographic or multi-gated acquisition scans is imperative in preventing permanent damage. Recent studies are suggesting that beta blockers or angiotensin converting enzyme inhibitors (ACEi)/Angiotensin receptor blockers (ARB) be started concomitantly with chemotherapy.
Methods: A retrospective study was done and total of 538 patients who underwent chemotherapy were included in the study. 54 patients were identified with non-ischemic cardiomyopathy; they were matched with a randomized control group. Statistical analysis was done to look for association between risk factors or pre-existing use of beta blockers or ACEi/ARB and cardiomyopathy.
Results: In the control group 19 patients were found to be on ACEi/ARB or Beta Blocker and 10 in the cardiomyopathy group. But no statistical significance was found between cardiomyopathy and use of these medications. The p-value came back to be 0.0962.
Association was checked between cardiomyopathy and risk factors including hypertension, hyperlipidemia, gender, smoking, Obesity, radiation and age. But no statistical significance was found between these risk factors and cardiomyopathy.
Conclusions: This study did not find any correlation between chemotherapy induced cardiomyopathy and the pre-existing conditions studied. The lack of correlation in previously identified risk factors may be a result of small sample size and because there was confounding data due to patients in both groups receiving beta
blockers and ACEi/ARBs. Taking into consideration treatment duration, dosages, and original indication for such medications could provide better insight into potential differences between groups.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1121-255
- 2017 American College of Cardiology Foundation